FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2803089126> ?p ?o ?g. }

• W2803089126 endingPage "1299" @default.
• W2803089126 startingPage "1291" @default.
• W2803089126 abstract "ObjectiveTo evaluate intraarticular onabotulinumtoxinA 400 U and 200 U in reducing symptoms of knee osteoarthritis (OA) in patients with nociceptive pain.DesignA multicenter, double-blind, randomized, placebo-controlled study was conducted in adults with knee OA and a painDETECT questionnaire score of ≤12 (indicating nociceptive pain). Patients were randomized to receive intraarticular onabotulinumtoxinA 400 U or 200 U or placebo (saline) in the study knee on a 1:1:2 ratio and were followed-up for 24 weeks posttreatment. The primary efficacy measure was the daily average numeric rating scale pain score for the study knee over 7 days at week 8. Secondary efficacy measures included the Western Ontario and McMaster Universities Osteoarthritis Index pain and physical function scores, the patient global impression of change score and the 7-day average worst pain score.ResultsOf the 176 enrolled patients, 158 completed the study. The daily average pain score was reduced by approximately two points for all treatments (week 8); the reduction was sustained throughout follow-up, with no significant between-group difference between onabotulinumtoxinA and placebo (both doses: 0.22 [95% confidence interval (CI): −0.33, 0.76]; 400 U: 0.42 [95% CI: −0.26, 1.10]; 200 U: −0.03 [95% CI: −0.70, 0.64]). Similar results were found for all secondary efficacy measures. Treatment-related adverse events occurred in 3.4% of the pooled onabotulinumtoxinA group and placebo group; none were serious.ConclusionsThere were no significant differences between onabotulinumtoxinA and placebo in reducing average pain score at week 8 compared with baseline in patients with knee OA. No safety concerns were identified.ClinicalTrials.gov identifierNCT02230956. To evaluate intraarticular onabotulinumtoxinA 400 U and 200 U in reducing symptoms of knee osteoarthritis (OA) in patients with nociceptive pain. A multicenter, double-blind, randomized, placebo-controlled study was conducted in adults with knee OA and a painDETECT questionnaire score of ≤12 (indicating nociceptive pain). Patients were randomized to receive intraarticular onabotulinumtoxinA 400 U or 200 U or placebo (saline) in the study knee on a 1:1:2 ratio and were followed-up for 24 weeks posttreatment. The primary efficacy measure was the daily average numeric rating scale pain score for the study knee over 7 days at week 8. Secondary efficacy measures included the Western Ontario and McMaster Universities Osteoarthritis Index pain and physical function scores, the patient global impression of change score and the 7-day average worst pain score. Of the 176 enrolled patients, 158 completed the study. The daily average pain score was reduced by approximately two points for all treatments (week 8); the reduction was sustained throughout follow-up, with no significant between-group difference between onabotulinumtoxinA and placebo (both doses: 0.22 [95% confidence interval (CI): −0.33, 0.76]; 400 U: 0.42 [95% CI: −0.26, 1.10]; 200 U: −0.03 [95% CI: −0.70, 0.64]). Similar results were found for all secondary efficacy measures. Treatment-related adverse events occurred in 3.4% of the pooled onabotulinumtoxinA group and placebo group; none were serious. There were no significant differences between onabotulinumtoxinA and placebo in reducing average pain score at week 8 compared with baseline in patients with knee OA. No safety concerns were identified." @default.
• W2803089126 created "2018-05-17" @default.
• W2803089126 creator A5003434565 @default.
• W2803089126 creator A5004110954 @default.
• W2803089126 creator A5007363152 @default.
• W2803089126 creator A5027937113 @default.
• W2803089126 creator A5036115140 @default.
• W2803089126 creator A5045941614 @default.
• W2803089126 creator A5064599465 @default.
• W2803089126 creator A5080292758 @default.
• W2803089126 date "2018-10-01" @default.
• W2803089126 modified "2023-10-04" @default.
• W2803089126 title "Efficacy and safety of single-dose onabotulinumtoxinA in the treatment of symptoms of osteoarthritis of the knee: results of a placebo-controlled, double-blind study" @default.
• W2803089126 cites W1513245939 @default.
• W2803089126 cites W1548981124 @default.
• W2803089126 cites W1599185368 @default.
• W2803089126 cites W1967057044 @default.
• W2803089126 cites W1974905386 @default.
• W2803089126 cites W1992951660 @default.
• W2803089126 cites W1994481205 @default.
• W2803089126 cites W2018004536 @default.
• W2803089126 cites W2030009013 @default.
• W2803089126 cites W2030674483 @default.
• W2803089126 cites W2047985623 @default.
• W2803089126 cites W2051133982 @default.
• W2803089126 cites W2058147305 @default.
• W2803089126 cites W2070974940 @default.
• W2803089126 cites W2085730477 @default.
• W2803089126 cites W2086936460 @default.
• W2803089126 cites W2108344016 @default.
• W2803089126 cites W2113079259 @default.
• W2803089126 cites W2129281457 @default.
• W2803089126 cites W2132309748 @default.
• W2803089126 cites W2135724744 @default.
• W2803089126 cites W2135956897 @default.
• W2803089126 cites W2154693681 @default.
• W2803089126 cites W2156933229 @default.
• W2803089126 cites W2161736885 @default.
• W2803089126 cites W2343036643 @default.
• W2803089126 cites W2530841354 @default.
• W2803089126 doi "https://doi.org/10.1016/j.joca.2018.05.001" @default.
• W2803089126 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29753118" @default.
• W2803089126 hasPublicationYear "2018" @default.
• W2803089126 type Work @default.
• W2803089126 sameAs 2803089126 @default.
• W2803089126 citedByCount "16" @default.
• W2803089126 countsByYear W28030891262019 @default.
• W2803089126 countsByYear W28030891262020 @default.
• W2803089126 countsByYear W28030891262022 @default.
• W2803089126 countsByYear W28030891262023 @default.
• W2803089126 crossrefType "journal-article" @default.
• W2803089126 hasAuthorship W2803089126A5003434565 @default.
• W2803089126 hasAuthorship W2803089126A5004110954 @default.
• W2803089126 hasAuthorship W2803089126A5007363152 @default.
• W2803089126 hasAuthorship W2803089126A5027937113 @default.
• W2803089126 hasAuthorship W2803089126A5036115140 @default.
• W2803089126 hasAuthorship W2803089126A5045941614 @default.
• W2803089126 hasAuthorship W2803089126A5064599465 @default.
• W2803089126 hasAuthorship W2803089126A5080292758 @default.
• W2803089126 hasBestOaLocation W28030891261 @default.
• W2803089126 hasConcept C126322002 @default.
• W2803089126 hasConcept C142724271 @default.
• W2803089126 hasConcept C168563851 @default.
• W2803089126 hasConcept C1862650 @default.
• W2803089126 hasConcept C197934379 @default.
• W2803089126 hasConcept C204787440 @default.
• W2803089126 hasConcept C27081682 @default.
• W2803089126 hasConcept C2776164576 @default.
• W2803089126 hasConcept C2779279471 @default.
• W2803089126 hasConcept C42219234 @default.
• W2803089126 hasConcept C44249647 @default.
• W2803089126 hasConcept C71924100 @default.
• W2803089126 hasConceptScore W2803089126C126322002 @default.
• W2803089126 hasConceptScore W2803089126C142724271 @default.
• W2803089126 hasConceptScore W2803089126C168563851 @default.
• W2803089126 hasConceptScore W2803089126C1862650 @default.
• W2803089126 hasConceptScore W2803089126C197934379 @default.
• W2803089126 hasConceptScore W2803089126C204787440 @default.
• W2803089126 hasConceptScore W2803089126C27081682 @default.
• W2803089126 hasConceptScore W2803089126C2776164576 @default.
• W2803089126 hasConceptScore W2803089126C2779279471 @default.
• W2803089126 hasConceptScore W2803089126C42219234 @default.
• W2803089126 hasConceptScore W2803089126C44249647 @default.
• W2803089126 hasConceptScore W2803089126C71924100 @default.
• W2803089126 hasFunder F4320332585 @default.
• W2803089126 hasIssue "10" @default.
• W2803089126 hasLocation W28030891261 @default.
• W2803089126 hasLocation W28030891262 @default.
• W2803089126 hasOpenAccess W2803089126 @default.
• W2803089126 hasPrimaryLocation W28030891261 @default.
• W2803089126 hasRelatedWork W1970458683 @default.
• W2803089126 hasRelatedWork W2051878809 @default.
• W2803089126 hasRelatedWork W2058225445 @default.
• W2803089126 hasRelatedWork W2076691999 @default.
• W2803089126 hasRelatedWork W2083092719 @default.
• W2803089126 hasRelatedWork W2150571925 @default.
• W2803089126 hasRelatedWork W2550787247 @default.
• W2803089126 hasRelatedWork W3082560859 @default.

• next